活血化瘀中药联合西医抗血小板药物在冠心病二级预防中的可能优势

史大卓

doi:10.3969/j.issn.1006-2157.2023.07.002

您当前的位置：

首页 >

文章列表页 >

活血化瘀中药联合西医抗血小板药物在冠心病二级预防中的可能优势

“中医药防治心血管疾病”专题 | 更新时间：2023-08-07

- 活血化瘀中药联合西医抗血小板药物在冠心病二级预防中的可能优势
- The superiority of combining Chinese medicinals for promoting blood circulation and removing blood stasis with antiplatelet drugs in the secondary prevention of coronary heart disease
- 北京中医药大学学报 2023年46卷第7期页码：897-901
- 作者机构：
  
  中国中医科学院西苑医院　北京　100091
- 作者简介：
  
  Prof. SHI Dazhuo, Ph.D., Chief Physician, Doctoral Supervisor. Xiyuan Hospital, China Academy of Chinese Medical Sciences, No.1, Xiyuan Caochang Road, Haidian District, Beijing 100091. E-mail: shidazhuo@126.com
- 基金信息：
  
  国家中医药管理局中医药创新团队及人才支持计划项目(ZYYCXTD-C-202007)
- DOI：10.3969/j.issn.1006-2157.2023.07.002
  中图分类号： R256.22
- 纸质出版日期：2023-07-30，
  
  网络出版日期：2023-05-12，
  
  收稿日期：2022-12-30，
- 稿件说明：
移动端阅览
史大卓. 活血化瘀中药联合西医抗血小板药物在冠心病二级预防中的可能优势[J]. 北京中医药大学学报, 2023,46(7):897-901.

SHI Dazhuo. The superiority of combining Chinese medicinals for promoting blood circulation and removing blood stasis with antiplatelet drugs in the secondary prevention of coronary heart disease[J]. Journal of Beijing University of Traditional Chinese Medicine, 2023,46(7):897-901.
史大卓. 活血化瘀中药联合西医抗血小板药物在冠心病二级预防中的可能优势[J]. 北京中医药大学学报, 2023,46(7):897-901. DOI： 10.3969/j.issn.1006-2157.2023.07.002.

SHI Dazhuo. The superiority of combining Chinese medicinals for promoting blood circulation and removing blood stasis with antiplatelet drugs in the secondary prevention of coronary heart disease[J]. Journal of Beijing University of Traditional Chinese Medicine, 2023,46(7):897-901. DOI： 10.3969/j.issn.1006-2157.2023.07.002.

摘要

抗血小板药物阿司匹林、氯吡格雷等是冠心病二级预防的基石，可明显改善患者的临床预后，但长期服用可增加出血风险和耐药性。近年来，临床研究显示，活血化瘀中药联合西医抗血小板药物可进一步降低冠心病患者的致残率和死亡率，且不增加出血风险，但证据水平有待进一步提高，以促进临床转化应用。因此，如何根据现代循证医学理念，拓展和深化活血化瘀中药联合西医抗血小板药物治疗冠心病的临床和机理研究，客观评价其疗效和安全性优势，阐释其生物作用机理，对冠心病的二级预防具有重要意义。

Abstract

Antiplatelet drugs such as aspirin and clopidogrel are the cornerstones of the secondary prevention of coronary heart disease (CHD)

which can significantly improve treatment outcomes; however

long-term use increases the risk of bleeding and drug resistance. Recent clinical studies have shown that the combination of Chinese medicinals for promoting blood circulation and removing blood stasis with antiplatelet drugs has further reduced the disability rate and mortality of patients with CHD without increasing the risk of bleeding

but the evidence needs to be further strengthened for clinical application. Therefore

to achieve the secondary prevention of CHD

it is important to expand the clinical and mechanistic studies on the prevention and treatment of CHD with Chinese medicinals for promoting blood circulation and removing blood stasis combined with antiplatelet drugs according to the requirements of evidence-based medicine

objectively evaluating its efficacy and safety advantages

and exploring its biological mechanism.

关键词

活血化瘀中药抗血小板药物冠心病二级预防

Keywords

promoting blood circulation for removing blood stasisChinese medicinalsantiplatelet drugscoronary heart disease(CHD)secondary prevention

references

中国心血管健康与疾病报告编写组．中国心血管健康与疾病报告2021概要[J]. 心脑血管病防治，2022, 22(4): 20-36.

YU Y, SPATZ ES, TAN Q, et al. Traditional Chinese Medicine Use in the Treatment of Acute Heart Failure in Western Medicine Hospitals in China: Analysis From the China PEACE Retrospective Heart Failure Study[J/OL]. J Am Heart Assoc，2019，8(15): e012776[2022-11-01]. https://www.ahajournals.org/doi/10.1161/JAHA.119.012776.

张缤纷，张文曦，奚肇庆. 活血化瘀中药抗血小板作用机制的研究综述[J].环球中医药，2020，13(5):943-946.

COENEN DM, MASTENBROEK TG, COSEMANS JMEM. Platelet interaction with activated endothelium: mechanistic insights from microfluidics[J]. Blood，2017，130(26):2819-2828.

YUSUF S, ZHAO F, MEHTA SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation[J]. N Engl J Med，2001，345(7):494-502.

STEINHUBL SR, BHATT DL, BRENNAN DM, et al. Aspirin to Prevent Cardiovascular Disease: The Association of Aspirin Dose and Clopidogrel With Thrombosis and Bleeding[J]. Ann Intern Med，2009，150(6):379-386.

CAYLA G, CUISSET T, SILVAIN J, et al. Prasugrel Monitoring and Bleeding in Real World Patients[J]. Am J Cardiol, 2013, 111(1): 38-44.

郭一洁，邹晓，司全金．抗血小板药物研究进展[J].中华老年多器官疾病杂志，2017，16(9):699-702.

LOPEZ MENENDEZ J, AVANZAS P, CALLEJO F, et al. Dual antiplatelet treatment after coronary artery bypass surgery[J/OL]. J Cardiothorac Surg, 2015:A102[2022-11-01]. https://link.springer.com/article/10.1186/1749-8090-10-S1-A102.

HANKEY GJ, EIKELBOOM JW. Aspirin resistance[J]. Lancet, 2006, 367(9510): 606-617.

DAVì G, PATRONO C. Platelet activation and atherothrombosis[J]. N Engl J Med, 2007, 357(24): 2482-2494.

刘玥，殷惠军，陈可冀. 芍药苷联合川芎嗪对肌动蛋白微丝诱导血小板活化及血小板凝溶胶蛋白水平的干预效应研究[J]. 中国中西医结合杂志，2020，40(3):313-317.

张可，马旭，韩淑燕，等．人参总皂苷与丹参总酚酸配伍对急性血瘀大鼠血液流变性的改善作用[J].中国药理学与毒理学杂志，2012，26(5) : 641-645.

WANG MM, XUE M, XU YG, et al. Panax notoginseng saponin is superior to aspirin in inhibiting platelet adhesion to injured endothelial cells through COX pathway in vitro[J]. Thromb Res, 2016, 141: 146-152.

何谨，龚云鹏，王博龙，等. 川芎嗪注射液与阿司匹林和氯吡格雷联用抗家兔血栓形成的作用[J]. 中国临床药理学杂志，2017, 33(7): 612-615.

寇娜．益气活血中药配伍联合双抗药物抗血栓作用及出血风险研究[D].北京：北京中医药大学，2016.

王铭铭，薛梅，杨琳，等. 益气活血中药配伍双联抗血小板药物对人脐静脉内皮细胞损伤和内皮血小板黏附的影响[J].中国中西医结合杂志，2016, 36(7): 842-848.

闫思雨，马丽红，郭彩霞，等．中西医结合改善冠心病PCI术后患者预后前瞻性队列研究[J].中国中西医结合杂志，2022, 42(11): 1300-1306.

SHANG QH, XU H, LU XY, et al. A multi-center randomized double-blind placebo-controlled trial of Xiongshao Capsule in preventing restenosis after percutaneous coronary intervention: a subgroup analysis of senile patients[J]. Chin J Integr Med, 2011, 17(9): 669-674.

LI JG, GAO ZY, ZHANG LJ, et al. Qing-Xin-Jie-Yu Granule for patients with stable coronary artery disease (QUEST Trial): A multicenter, double-blinded, randomized trial[J/OL]. Complement Ther Med, 2019, 47: 102209[2022-11-01]. https://www.sciencedirect.com/science/article/abs/pii/S0965229919312531?via%3Dihub.

GUO M, WANG PL, DU JP, et al. Xinyue Capsule in patients with stable coronary artery disease after percutaneous coronary intervention: a multicenter, randomized, placebo-controlled trial[J/OL]. Pharmacol Res, 2020, 158: 104883[2022-11-01]. https://linkinghub.elsevier.com/retrieve/pii/S1043661820311919.

SHANG HC, ZHANG JH, YAO C, et al. Qi-shen-yi-qi dripping pills for the secondary prevention of myocardial infarction: a randomised clinical trial[J/OL]. Evid Based Complement Alternat Med, 2013: 738391[2022-11-01]. https://www.hindawi.com/journals/ecam/2013/738391/.

WANG WT, YANG L, SONG L, et al. Combination of Panax notoginseng saponins and aspirin potentiates platelet inhibition with alleviated gastric injury via modulating arachidonic acid metabolism[J/OL]. Biomed Pharmacother. 2021, 134: 111165[2022-11-01]. https://linkinghub.elsevier.com/retrieve/pii/S0753332220313585.

李昊娲，农一兵，林谦. 丹参注射液与抗血栓药合用对急性冠脉综合征患者出血风险研究[J]. 中华中医药杂志，2011, 26(10): 2388-2392.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

三步序贯法对激素撤减过程中哮喘气道重塑模型大鼠肺泡灌洗液内TGF-β1/Smad信号通路相关指标浓度的影响

过量使用含汞中药外用制剂引起的肾功能指标改变与肾脏病理形态学的关系

中药治疗糖尿病足溃疡随机对照试验的系统评价